OS Therapies (OSTX) Competitors $1.68 +0.10 (+6.33%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.73%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. DRUG, YMAB, CTMX, NLTX, ELDN, OGI, GNFT, FDMT, CYBN, and LIMNShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Bright Minds Biosciences (DRUG), Y-mAbs Therapeutics (YMAB), CytomX Therapeutics (CTMX), Neoleukin Therapeutics (NLTX), Eledon Pharmaceuticals (ELDN), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Cybin (CYBN), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors Bright Minds Biosciences Y-mAbs Therapeutics CytomX Therapeutics Neoleukin Therapeutics Eledon Pharmaceuticals Organigram Global GENFIT 4D Molecular Therapeutics Cybin Liminatus Pharma Bright Minds Biosciences (NASDAQ:DRUG) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment. Which has better earnings & valuation, DRUG or OSTX? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than OS Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-68.94OS TherapiesN/AN/A-$7.79M-$0.86-1.95 Does the media favor DRUG or OSTX? In the previous week, OS Therapies had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for OS Therapies and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.90 beat OS Therapies' score of -0.19 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Very Positive OS Therapies Neutral Do institutionals & insiders have more ownership in DRUG or OSTX? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 13.8% of OS Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer DRUG or OSTX? Bright Minds Biosciences presently has a consensus target price of $83.25, indicating a potential upside of 235.41%. OS Therapies has a consensus target price of $18.00, indicating a potential upside of 971.43%. Given OS Therapies' stronger consensus rating and higher possible upside, analysts clearly believe OS Therapies is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Is DRUG or OSTX more profitable? OS Therapies' return on equity of 0.00% beat Bright Minds Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% OS Therapies N/A N/A -569.57% SummaryBright Minds Biosciences beats OS Therapies on 7 of the 13 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$47.21M$752.12M$5.52B$20.64BDividend YieldN/A4.84%4.25%3.68%P/E Ratio-1.951.4328.1527.27Price / SalesN/A25.51438.3355.20Price / CashN/A19.5635.5321.88Price / BookN/A6.608.234.60Net Income-$7.79M-$4.53M$3.23B$995.22M7 Day Performance1.20%1.40%-0.01%-0.80%1 Month Performance-11.58%1.30%5.61%3.55%1 Year PerformanceN/A3.42%26.52%7.35% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.2221 of 5 stars$1.68+6.3%$18.00+971.4%N/A$47.21MN/A-1.95N/AAnalyst ForecastDRUGBright Minds Biosciences2.4049 of 5 stars$27.33-3.7%$83.25+204.6%+2,288.2%$192.40MN/A-75.91N/APositive NewsYMABY-mAbs Therapeutics4.1598 of 5 stars$4.22-1.9%$15.60+269.7%-67.5%$191.08M$87.68M-6.59150Positive NewsCTMXCytomX Therapeutics4.1501 of 5 stars$2.37-5.2%$5.33+125.0%+70.2%$191.07M$138.10M4.94170Positive NewsNLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-47.7%$188.81MN/A-6.4690ELDNEledon Pharmaceuticals1.8231 of 5 stars$3.11+1.0%$9.00+189.4%+47.5%$186.23MN/A-1.4810Positive NewsAnalyst RevisionOGIOrganigram Global1.1408 of 5 stars$1.39-2.8%N/A-16.4%$186.18M$117.47M13.90860News CoverageGNFTGENFIT2.3059 of 5 stars$3.69-4.8%$13.00+252.7%-14.0%$184.30M$76.77M0.00120FDMT4D Molecular Therapeutics2.3641 of 5 stars$3.95-6.8%$29.56+648.2%-84.6%$182.98M$23K-1.24120CYBNCybin2.4745 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050LIMNLiminatus PharmaN/A$6.93-23.2%N/AN/A$180.25MN/A0.00N/A Related Companies and Tools Related Companies Bright Minds Biosciences Competitors Y-mAbs Therapeutics Competitors CytomX Therapeutics Competitors Neoleukin Therapeutics Competitors Eledon Pharmaceuticals Competitors Organigram Global Competitors GENFIT Competitors 4D Molecular Therapeutics Competitors Cybin Competitors Liminatus Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OSTX Stock Alerts